Prosensa Therapeutics BV is banking an up-front payment of £16 million (US$25.3 million) and could earn up to £412 million more from an RNA-based drug development alliance with GlaxoSmithKline plc in the X-linked neuromuscular disorder Duchenne's muscular dystrophy (DMD). (BioWorld International)

Almost 15 months after halting a Phase I trial of RhuDex following the death of a trial volunteer in Edinburgh, Scotland, the UK's Medicines and Healthcare products Regulatory Agency has lifted the clinical hold on the study. (BioWorld International)